Filing identity and reporting period
Important metadata mismatch: The request identifies Tuhura Biosciences, Inc. and “2021 Q3,” but the supplied filing is Kintara Therapeutics, Inc.’s Form 10-Q for the quarter ended March 31, 2022, covering its fiscal third quarter and nine months ended March 31, 2022. The summary below reflects the filing provided, not the requested company or period.
Kintara is a clinical-stage oncology drug developer with no revenue to date. Its lead programs are VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. Financial amounts below are U.S. dollars in thousands unless otherwise stated.
Financial results and liquidity
| Metric | Three months ended March 31, 2022 | Nine months ended March 31, 2022 | Comparable 2021 period |
|---|---|---|---|
| Revenue | None | None | None |
| Research and development expense | $3,474 | $11,169 | $3,843 quarterly; $7,784 nine-month |
| General and administrative expense | $1,884 | $6,055 | $2,762 quarterly; $7,091 nine-month |
| Net loss | $5,356 | $17,215 | $6,635 quarterly; $31,566 nine-month |
| Loss per share | $0.11 | $0.45 | $0.23 quarterly; $1.47 nine-month |
| Cash used in operations | Not provided separately | $15,400 | $14,171 nine-month |
Cash and equivalents were $8,839 at March 31, 2022, down from $10,537 at June 30, 2021. Current assets were $10,093 and current liabilities $3,240, giving working capital of $6,853 and a current ratio of about 3.1. Total assets were $12,798, total liabilities $3,412, and stockholders’ equity $9,386. The balance sheet shows no conventional borrowing balance; liabilities principally comprise payables and a $172 milestone payment liability. No operating margins are meaningful because the company reported no revenue.
Nine-month financing cash inflows were $13,702, mainly $13,634 net proceeds from a September 2021 equity-and-warrant offering. Cash declined by $1,698 over the nine-month period. On April 14, 2022, after quarter-end, the company raised approximately $7,900 net through another registered direct offering of shares and warrants.
Material changes versus comparable periods
- Quarterly net loss narrowed by $1,279 versus 2021, as R&D and G&A expenses fell; management attributed this largely to lower share-based compensation and certain personnel, database, and professional costs.
- Nine-month net loss narrowed by $14,351, substantially because the prior-year period included a $16,094 noncash acquired in-process R&D charge and $500 of merger costs. R&D expense nevertheless rose 43%, principally reflecting the longer period of GBM AGILE study activity and REM-001 study preparation.
- Operating cash use increased by $1,229 year over year, despite the lower reported net loss.
- Common shares issued increased to 49.306 million at March 31, 2022, from 32.740 million at June 30, 2021. The company also had substantial warrants, options, and convertible Series C preferred stock outstanding, creating potential dilution.
- The 2021 comparison includes unusual noncash preferred-stock accounting: a $3,181 deemed dividend. In the 2022 nine-month period, a $2,462 Series C stock dividend increased loss attributable to common stockholders, although it was noncash.
Outlook, risks, and unusual items
- Going concern: Management disclosed substantial doubt about Kintara’s ability to continue as a going concern within one year of the filing. Even including the April financing proceeds, it expected available cash to fund planned operations for less than one year and stated that additional financing is required. There is no assurance that financing or partnership plans will succeed; programs may be delayed, reduced, or discontinued.
- Clinical outlook: Management expected VAL-083 GBM AGILE topline results around the end of calendar 2023. It planned to begin enrollment in a 15-patient REM-001 confirmatory study by mid-2022, with topline results targeted for Q3 2023. These are forward-looking targets, not guarantees.
- Trial and manufacturing risks: The company reported no significant COVID-19-related impact on GBM AGILE enrollment at the time, but said COVID-related contract manufacturing and supply delays could affect REM-001 timing. Clinical outcomes, regulatory decisions, trial execution, and manufacturing remain material uncertainties.
- Clinical expense commitment: Kintara reported $5,770 of expense for the GBM AGILE study during the nine months and a $2,600 CRO deposit intended for future invoices or refund beyond 12 months. The company may terminate the study but remains responsible for amounts due and certain nonrefundable costs.
- Capital structure and contingent obligations: Series C preferred stock carries conversion and stock-dividend features; the filing estimates 14.496 million common conversion shares for outstanding Series C shares, before associated preferred-stock warrants. Potential REM-001 milestone payments are $300 upon specified development/financing events and $700 upon regulatory approval.
- Management said disclosure controls were effective and that there were no material changes in internal control over financial reporting. The filing reported no legal proceedings and no material changes to previously disclosed risk factors.
Most important facts to verify
- Confirm the intended issuer and period: the supplied filing is Kintara’s quarter ended March 31, 2022, not a Tuhura Biosciences filing or a 2021 quarter.
- Review the going-concern disclosure and the company’s subsequent cash position, burn rate, and financing needs; the filing estimates runway of less than one year even after the April 2022 offering.
- Verify current fully diluted share count and the terms and potential dilution of outstanding warrants, options, and Series C preferred stock.
- Check progress and actual timing of GBM AGILE and REM-001 clinical milestones, including REM-001 manufacturing and enrollment delays.
- Reconcile the April offering share count: the notes report 16,266 shares in thousands, while MD&A states 16,226,416 shares; clarify the definitive amount against the offering documents.